Affiliations 

  • 1 Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt
  • 2 Department of Medicine, University of California San Francisco Comprehensive Cancer Center, San Francisco, CA 94158, USA
  • 3 Clinical Oncology Department, Kasr Alainy School of Medicine, Cairo University, Giza 12613, Egypt
  • 4 Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, MedStar Health, Washington, DC 20007, USA
  • 5 Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
  • 6 Breast Center, Clinique de Genolier, 1272 Genolier, Switzerland
  • 7 Department of Hematology & Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
  • 8 Breast Health Global Initiative, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98195, USA
  • 9 Department of Pathology, Clermont Auvergne University, INSERM U1240 "Molecular Imaging and Theranostic Strategies", Center Jean Perrin, Montalembert, 63000 Clermont-Ferrand, France
  • 10 Department of Surgery, Oncology and Gastroenterology, University of Padova, Istituto Oncologico Veneto IOV IRCCS, 35128 Padova, Italy
  • 11 Department of Internal Medicine, Division of Hematology Oncology, American University of Beirut Medical Center, Beirut 1107 2020, Lebanon
  • 12 Subang Jaya Medical Centre, Kuala Lumpur 47500, Malaysia
  • 13 Hematology and Oncology Department, Saint Joseph University, Beirut 1104 2020, Lebanon
  • 14 Iridium Kankernetwerk and Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Wilrijk-Antwerp, Belgium
  • 15 Clinical oncology Department, Menoufia University, Shebin Elkom 51132, Egypt
  • 16 Department of Surgery, Surgical Oncology Division, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
  • 17 Department of Breast Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
  • 18 Institut Universitaire de Cancérologie AP-HP. Sorbonne Université, INSERM U938, 75013 Paris, France
  • 19 Breast & Endocrine Surgery Unit, Marmara University School of Medicine, University Hospital, Istanbul 34722, Turkey
  • 20 Federal State Budgetary Institution "NN Blokhin National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation, 127994 Moscow, Russia
  • 21 Surgical Oncology Department, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
  • 22 Scientific Directorate, IRCCS European Institute of Oncology (IEO), and University of Milan, 20122 Milan, Italy
  • 23 Al Hyatt Oncology Practice, Amman 11183, Jordan
  • 24 Department of Clinical Oncology, Alexandria School of Medicine, Alexandria 21131, Egypt
  • 25 Russian Association of Oncological Mammology, Department of Breast Tumours of Federal State Budgetary Institution "Petrov Research Institute of Oncology", 197758 Saint Petersburg, Russia
  • 26 College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Adult Medical Oncology, Princess Noorah Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs-Western Region, Jeddah 22384, Saudi Arabia
  • 27 Department of General Surgery, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt
  • 28 Department of Pathology, Ain shams University, Cairo 11566, Egypt
  • 29 Oncology Department, Alfaisal university, Alhabib Hospital, Riyad 11533, Saudi Arabia
  • 30 Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China
  • 31 The School of Public Health, University of Adelaide, Adelaide 5005, Australia
  • 32 Biomedical Genomics & Oncogenetics Research Laboratory, Faculty of Sciences and Techniques of Tangier, Abdel Malek Essaadi University, Tangier 90000, Morocco
Cancers (Basel), 2021 May 08;13(9).
PMID: 34066769 DOI: 10.3390/cancers13092262

Abstract

Background: The management of patients with triple-negative breast cancer (TNBC) is challenging with several controversies and unmet needs. During the 12th Breast-Gynaecological & Immuno-oncology International Cancer Conference (BGICC) Egypt, 2020, a panel of 35 breast cancer experts from 13 countries voted on consensus guidelines for the clinical management of TNBC. The consensus was subsequently updated based on the most recent data evolved lately. Methods: A consensus conference approach adapted from the American Society of Clinical Oncology (ASCO) was utilized. The panellists voted anonymously on each question, and a consensus was achieved when ≥75% of voters selected an answer. The final consensus was later circulated to the panellists for critical revision of important intellectual content. Results and conclusion: These recommendations represent the available clinical evidence and expert opinion when evidence is scarce. The percentage of the consensus votes, levels of evidence and grades of recommendation are presented for each statement. The consensus covered all the aspects of TNBC management starting from defining TNBC to the management of metastatic disease and highlighted the rapidly evolving landscape in this field. Consensus was reached in 70% of the statements (35/50). In addition, areas of warranted research were identified to guide future prospective clinical trials.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.